AKCA
Akcea Therapeutics
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 1.84B; Volume: 250.75K; AvgVol 3m: 508.74K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.85; EPS growth quarter/prev quarter: -21.00%;
EPS growth this year: 115.80%; EPS growth past 5 years: 19.40%;
EPS ttm: -0.85;
P/S: 5.48; P/B: 2.92; P/Cashflow: 4.73; P/FCF: 19.26;
Sales: 336.55M; Sales growth quarter/prev quarter: -15.80%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 94.90%; Profit Margin: -12.30%; Operating Margin: -13.60%;
ROA – return on assets: -8.00%; ROE – return on equity: -8.90%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.40%; Insider Transactions:-2.40%;
Institutional Ownership: 19.80%; Institutional Transactions: -3.84%;
Data update: 07.10.2020.